Figure 4.

Subretinal AAV5 Treatment Does Not Result in Systemic Response

We examined whether mice treated with either AAV5-VMD2-mCherry or AAV5-VMD2-CR2-fH developed CR2-fH antibodies. One month following subretinal injection of AAV5-VMD2-mCherry or AAV5-VMD2-CR2-fH, sera were collected. Two concentrations of CR2-fH expressed by CHO cells (1× = 20 μL and 2× = 40 μL) were probed with sera from mice injected with either CR2-fH (panels 3, 3′, 5, and 5′) or mCherry (panels 2, 2′, 4, and 4′) as a primary antibody and with either IgG or IgM as a secondary antibody. CR2-specific antibodies were used as a positive control identifying the 72 KDa protein in control lanes (panels 1 and 1′).